Compare TUYA & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | ATRC |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2021 | 2005 |
| Metric | TUYA | ATRC |
|---|---|---|
| Price | $2.31 | $28.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.49 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.1M | 494.6K |
| Earning Date | 05-19-2026 | 04-28-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $201,630,000.00 |
| Revenue This Year | $13.76 | $15.27 |
| Revenue Next Year | $11.90 | $12.21 |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $1.87 | $27.31 |
| 52 Week High | $2.95 | $43.18 |
| Indicator | TUYA | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 40.46 |
| Support Level | $2.24 | $28.60 |
| Resistance Level | $2.46 | $30.90 |
| Average True Range (ATR) | 0.10 | 1.07 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 33.33 | 43.13 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.